More than 50 medtech companies, including 11 of the top 20, have adopted ³ΤΉΟ±¬ΑΟ clinical applications for greater efficiency and speed
PLEASANTON, CA β June 11, 2025 β ³ΤΉΟ±¬ΑΟ Systems (NYSE: VEEV) today announced that more than 50 medtech companies, including 11 of the top 20 medtechs and seven of the top 10 medtech clinical research organizations (CROs), have selected ³ΤΉΟ±¬ΑΟ Clinical Platform applications to simplify and streamline medical device and diagnostic studies. With increasing regulatory requirements and evolving markets, medtech companies are moving away from siloed legacy solutions to modern connected applications from ³ΤΉΟ±¬ΑΟ MedTech.
With a growing number of medical device and diagnostic clinical trials executed on ³ΤΉΟ±¬ΑΟ Clinical applications, companies can gain the scalability to grow while maintaining compliance with local, regional, and global regulations. Medtechs of all sizes use ³ΤΉΟ±¬ΑΟ to drive improvements, with customers achieving 50% faster study build times with ³ΤΉΟ±¬ΑΟ EDC and 80% reductions in duplicate trial documents with ³ΤΉΟ±¬ΑΟ eTMF.
βItβs exciting to partner with the industry as it moves to ³ΤΉΟ±¬ΑΟ MedTech for a complete and connected medical device and diagnostics clinical trials infrastructure,β said Kevin Liang, vice president of clinical strategy at ³ΤΉΟ±¬ΑΟ MedTech. βWeβre working with leading medtechs to advance study execution, collaboration, and innovation to bring life-changing products to patients faster.β
What the medtech clinical industry is saying about ³ΤΉΟ±¬ΑΟ:
“With ³ΤΉΟ±¬ΑΟ EDC, weβve partnered closely with their team to enhance the global library and develop reusable standards.,β said Leianne Ebert, head of clinical data operations at Alcon. βWe focused on getting standards right, and that commitment drove 50% standardization in one year, boosting our compliance with our global library.β
“³ΤΉΟ±¬ΑΟ allows us to collect study data consistently in a manner that regulatory agencies will accept,β said Kimberly Dorsch, vice president of global clinical affairs at LifeNet Health. βWhether itβs a registry study or an IDE/IND study supporting a PMA/BLA, the data’s going to be collected the exact same way and in a compliant manner.”
“Since implementing ³ΤΉΟ±¬ΑΟ eTMF, we’ve reduced our quality control time by over 90% and decreased our document creation times significantly,” said Matt Christensen, senior vice president, global clinical and medical affairs at Smith+Nephew.
Learn more about ³ΤΉΟ±¬ΑΟ Clinical Platform applications for medtech at .
About ³ΤΉΟ±¬ΑΟ Systems
³ΤΉΟ±¬ΑΟ (NYSE: VEEV) is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³ΤΉΟ±¬ΑΟ serves more than 1,000 customers, ranging from the worldβs largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, ³ΤΉΟ±¬ΑΟ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
³ΤΉΟ±¬ΑΟ Forward-looking Statements
This release contains forward-looking statements regarding ³ΤΉΟ±¬ΑΟβs products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at .
###
Contact:
Deivis Mercado
³ΤΉΟ±¬ΑΟ Systems
925-226-8821
deivis.mercado@veeva.com